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LETTER TO THE EDITOR
The Effect of Cabergoline on Clinical and Laboratory 
Findings in Active Rheumatoid Arthritis 
 
 
Dear Editor, 
Rheumatoid arthritis (RA) is a chronic systemic in-
flammatory disorder affecting about 1% of the world 
population.
1 In recent years, biologic agents were in-
troduced for many aspects of medicine including RA, 
but their cost and potential side effects prohibited its 
widespread use.  
Dopamine agonists such as bromocriptine and 
cabergoline decreased the prolactin synthesis and se-
cretion by binding of the drug to cell-surface dopa-
mine receptors.
2  
Prolactin is secreted not only by anterior pituitary 
gland, but also by immune cells and it was shown that 
it can stimulate the immune cells by binding to pro-
lactin receptors.
3 Prolactin receptors were exclusively 
expressed on fibroblast like synovial cells and lym-
phocytes infiltrating into the synovium in patients 
with RA.
4 It has demonstrated that PRL can enhance 
RA synovial cell proliferation. There are four open 
trials about bromocriptine
5-8 and one case report about 
cabergoline
9 in RA treatment. Cabergoline is an ergot 
dopamine agonist that is administered once or twice a 
week and has much less tendency to cause nausea 
than bromocriptine.
10 
This study is a pilot randomized double blind clin-
ical trial carried out from September 2009 to May 
2010, on 10 patients with active RA who had been 
referred to Rheumatology Clinic in Sari, Iran. RA 
was defined according to ACR in 1987 and criteria 
for disease activity included existence of 4 swollen 
joints plus 2 of the followings criteria (i) Existence of 
6 tender joints, (ii) Morning stiffness more than 30 
minutes and (iii) Erythrocyte sedimentation rate 
(ESR) more than 28 mm/h.
11,12 
The patients suffered from active RA despite re-
ceiving prednisolone and DMARDs for at least 3-6 
months. The study was approved by Ethics Committee 
of Mazandaran University of Medical Sciences   
and was recorded in IRCT (IRCT code: 
IRCT138802061828N2). All patients signed informed 
consent. Patients with psychosis, pregnancy or lacta-
tion were excluded from the study. Patients continued 
their drugs with the same dose and kind of DMARD.  
Patients were randomly divided into two groups to 
receive 1 mg/week of cabergoline (Pharmacia and 
Upjohn SPA, Italy) or placebo (Sari, Iran, Pharmacy 
Faculty). The two groups were similar in terms of 
disease duration and activity and main anti-
rheumatoid therapy. In first step, patients took caber-
goline or placebo for 3 months and after 1 month, 
they used another drug for another 3 months period. 
Changes in disease activity in the beginning of the 
study and at 3
rd, 4
th and 7
th month of treatment and 
possible side effects were recorded.  
Statistical analysis was done by t-test for quantita-
tive variables; pair t test for comparison before and 
after interventions, and Wilcoxon signed test and 
Friedman for non-parametric methods. Non-
parametric statistical analysis was done by Wilcoxon 
signed and Friedman Exact test for comparison before 
and after interventions. 
Ten female patients with active RA entered this 
study. The study was followed for 9 patients. One 
patient in first group was excluded because of com-
plain of vertigo and vomiting. The mean age of pa-
tients was 55.6±9.5 years, mean of disease duration 
was 12.1±6.0 (years), morning stiffness of 30.5±41.2 
minutes, tender and swollen joint count of 7.4± 2.8 
and 5.1±1.8, and patient assessment of pain and glob-
al assessment of disease activity were 6.4±3.0 and 
5.5±2.9 according to visual analogue scale(VAS). 
PRL level was 9.4±7.0 (ng/ml) and mean for ESR 
was 35.0±14.4 (mm/h). After intervention by caber-
goline, prolactin level decreased from 10.6±4.3 to 
6.4±5.8 (ng/ml) (p=0.188) and by placebo it increased 
from 9.9±10.7 to 15.0±8.4 (ng/ml) (p=0.375). We 
compared changes in diseases activity by cabergoline 
and placebo as shown in Table 1. 
In this study, improvement of tender and swollen 
joint count, patient assessment of pain and patient 
global assessment of disease activity were significant 
when patients were treated by cabergoline. Prolactin 
is secreted not only by anterior pituitary gland, but 
also by immune cells that may have small effect on 
total serum prolactin level and a significant effect on 
immunomedulatory system, so cabergoline sup-
pressed both kinds of prolactin. The improvement in 
RA activity may be due to a significant suppression in 
secretion of prolactin by immune cells without a sig-
nificant change in prolactin level. Thus, we noticed Mobini et al. 
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significant improvement in patients receiving caber-
goline without a large decrease in prolactin level. 
Dougados et al. did not find any difference by bro-
mocriptine in clinical and laboratory measures of the 
disease activity in 6 RA patients.
5 Another study by 
Marguerie et al. in 30 patients with active RA showed 
some clinical improvement by bromocriptine in com-
parison to penicillamine.
6 Mader and Figueroa demon-
strated clinical improvement by bromocriptine too.
7,8 
Erb and coworkers reported a patient with severe un-
controlled RA that improved rapidly after treatment for 
coincidental hyperprolactinemia,
9 and Eijsbouts et al. 
tried on quinagolide for 6 months and despite suppres-
sion of PRL level, there was not any improvement in 
clinical or laboratory findings.
13 This study is the first, 
clinical trial about cabergoline in RA. It was a small and 
pilot study and we suggest future studies with more 
samples and with different dosages and intervals of pro-
lactin inhibitors especially cabergoline. Two of the pa-
tients did not have a good tolerance with 1 mg/week of 
cabergoline, thus, we suggested administration of a low-
er dosage and a 2 times/week. Cabergoline is long act-
ing and its usage and cost is acceptable and it has little 
complications. These factors are reasonable to study 
more about cabergoline in RA and other rheumatologic 
disorders that formerly have shown improvement by 
dopamine agonists. 
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